What is the recommended cefuroxime dose for treating acute cholecystitis in a patient with normal renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cefuroxime Dosing for Cholecystitis

For acute cholecystitis in patients with normal renal function, cefuroxime should be dosed at 1.5 grams IV every 8 hours, with treatment duration of 4 days for uncomplicated cases in immunocompetent patients, or up to 7 days for complicated cases or immunocompromised/critically ill patients.

Dosing Regimen

The FDA-approved dosing for severe or complicated infections is 1.5 grams IV every 8 hours 1. This dose is specifically indicated for serious infections and aligns with the severity of acute cholecystitis requiring antibiotic therapy.

For cholecystitis specifically:

  • Uncomplicated cholecystitis: If early cholecystectomy (within 7-10 days) is planned, use single-dose prophylaxis only with no post-operative antibiotics 2
  • Complicated cholecystitis with adequate source control: 1.5g IV q8h for 4 days in immunocompetent, non-critically ill patients 2
  • Complicated cholecystitis in critically ill/immunocompromised: 1.5g IV q8h for up to 7 days based on clinical response 2

Clinical Context and Guidelines

The 2024 Italian Council guidelines for intra-abdominal infections do not list cefuroxime as a first-line agent for cholecystitis 2. For non-critically ill immunocompetent patients with adequate source control, they recommend amoxicillin/clavulanate 2g/0.2g q8h, while critically ill patients should receive piperacillin/tazobactam 2. However, cefuroxime remains an acceptable second-generation cephalosporin alternative, particularly when first-line agents are unavailable or contraindicated.

Cefuroxime achieves therapeutic concentrations in gallbladder wall tissue (the primary site of inflammation) and bile, even with cystic duct obstruction, as it diffuses from the bloodstream 3. This pharmacokinetic property makes it suitable for biliary infections.

Duration of Therapy

Stop antibiotics after 4 days if:

  • Source control is adequate (successful cholecystectomy)
  • Patient is immunocompetent and not critically ill
  • Clinical improvement is evident 2

Extend to 7 days if:

  • Patient is immunocompromised or critically ill
  • Ongoing signs of infection persist
  • Source control is delayed or inadequate 2

Any patient with ongoing signs of infection beyond 7 days warrants diagnostic re-evaluation 2.

Renal Dosing Adjustments

For patients with renal impairment, adjust as follows 1:

  • CrCl >20 mL/min: 750mg-1.5g q8h (standard dosing)
  • CrCl 10-20 mL/min: 750mg q12h
  • CrCl <10 mL/min: 750mg q24h
  • Hemodialysis: Additional dose after dialysis

Important Caveats

Cefuroxime is not a guideline-recommended first-line agent for cholecystitis. Recent evidence shows only 45% adherence to IDSA-recommended antibiotics (cefazolin, ceftriaxone, or cefuroxime) for mild-to-moderate cholecystitis 4. While cefuroxime is listed as an acceptable option, cefazolin or ceftriaxone are preferred for community-acquired biliary infections due to better guideline support.

For surgical prophylaxis in cardiac or vascular surgery, cefuroxime dosing is 1.5g IV plus 0.75g in priming, with reinjection of 0.75g every 2 hours intraoperatively 5. However, for cholecystectomy prophylaxis specifically, single-dose cefazolin is the standard 2.

The most common pathogens in acute cholecystitis are E. coli, Klebsiella, Streptococcus, and Enterococcus species 6. Cefuroxime provides adequate coverage for most community-acquired biliary pathogens, though it lacks reliable enterococcal coverage—this is generally acceptable as enterococcal coverage is not routinely required for community-acquired infections unless the patient is immunosuppressed 7.

Related Questions

For a patient admitted with community‑acquired bacterial sepsis and acute calculous cholecystitis who received 5 days of ceftriaxone followed by 7 days of meropenem, now pain‑free and ready for discharge, should antibiotics be continued at home?
What antibiotics, dosing, and duration are recommended for treating acute cholecystitis in adults, and what alternative regimens should be used for β‑lactam allergy or when Enterococcus coverage is required?
What antibiotic is appropriate for an 86-year-old woman with ultrasound-confirmed acute cholecystitis?
What antibiotics, dosing, and duration are recommended for the treatment of acute cholecystitis, including alternatives for β‑lactam allergy and severe sepsis?
What is the recommended medical management for acute cholecystitis?
What are the indications for obtaining a chest radiograph in a 3‑year‑old child presenting with fever and cough?
What are the possible autoimmune causes of a scalp rash in a patient who also has asthma?
What is the appropriate dosing regimen for oral prednisolone and dexamethasone ophthalmic suspension in a patient with anterior uveitis, and how should follow‑up with the eye specialist be arranged?
Given negative ANCA (anti‑neutrophil cytoplasmic antibodies), negative anti‑centromere antibody, negative anti‑Smith and anti‑double‑stranded DNA antibodies, negative anti‑Ro (SS‑A) and anti‑La (SS‑B) antibodies, negative anti‑cardiolipin IgG, IgM, and IgA, normal complement C3 and C4 levels, and negative anti‑thyroid peroxidase antibody, what is the most likely diagnosis?
After administering carbetocin (100 µg IV or IM), how long should one wait before initiating an oxytocin infusion?
Does coffee consumption influence the development or growth of a breast fibroadenoma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.